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Abstract
Non-myeloablative allogeneic haematopoietic stem cell transplantation (HSCT) is rarely achievable clinically, except
where donor cells have selective advantages. Murine non-myeloablative conditioning regimens have limited clinical
success, partly through use of clinically unachievable cell doses or strain combinations permitting allograft
acceptance using immunosuppression alone. We found that reducing busulfan conditioning in murine syngeneic
HSCT, increases bone marrow (BM):blood SDF-1 ratio and total donor cells homing to BM, but reduces the
proportion of donor cells engrafting. Despite this, syngeneic engraftment is achievable with non-myeloablative
busulfan (25 mg/kg) and higher cell doses induce increased chimerism. Therefore we investigated regimens
promoting initial donor cell engraftment in the major histocompatibility complex barrier mismatched CBA to C57BL/6
allo-transplant model. This requires full myeloablation and immunosuppression with non-depleting anti-CD4/CD8
blocking antibodies to achieve engraftment of low cell doses, and rejects with reduced intensity conditioning (≤75
mg/kg busulfan). We compared increased antibody treatment, G-CSF, niche disruption and high cell dose, using
reduced intensity busulfan and CD4/8 blockade in this model. Most treatments increased initial donor engraftment,
but only addition of co-stimulatory blockade permitted long-term engraftment with reduced intensity or non-
myeloablative conditioning, suggesting that signal 1 and 2 T-cell blockade is more important than early BM niche
engraftment for transplant success.
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Introduction
Haematopoietic stem cell transplantation (HSCT) is used to
treat several genetic disorders, where a diffusible factor
delivered by donor cells can complement the disease. Both the
dose of protein or enzyme delivered by donor cells and the
level of donor chimerism achieved are important to achieve
maximal correction, as illustrated in the lysosomal disease
Mucopolysaccharidosis I (MPS I) Hurler [1]. HSCT is usually
limited to life-threatening genetic disorders due to the risks
associated with myeloablative conditioning (MAC) regimens
required to prevent transplant rejection. To expand the
application of HSCT to broader indications, such as attenuated
diseases, reduced intensity conditioning (RIC) or non-
myeloablative conditioning (NMC) would be preferred, but this
can lead to transplant rejection or low donor chimerism [1,2].
Graft rejection involves multiple mechanisms [3], but the
most widely used target in RIC is the T cell. Numerous RIC
regimens for allogeneic HSCT targeting the T cell have been
determined in mice (Table 1), but their clinical applicability has
been limited, partly due to determination of mouse regimens in
non-stringent transplant settings [4-6], and others have been
determined using clinically unachievable cell doses [7-10].
Non-depleting anti-CD4 and anti-CD8 monoclonal antibodies
(mAbs) with anti-CD40L costimulation blockade achieved
25-40% donor chimerism using moderate cell doses (20x106),
but only in permissive strain combinations, whilst C57BL/6
recipients are resistant to this method of transplant tolerance
generation [5,6,11]. In more stringent allo-transplant models
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using C57BL/6 recipients and MHC mismatched donor cells,
rejection is often overcome using high cell doses and/or some
myeloablation. T cell depleting anti-CD4 and anti-CD8 mAbs
with very high cell doses (200x106) and 7Gy thymic irradiation
(TI) can achieve 20-35% donor chimerism, but only 10-15% if
3.5Gy is used [7]. In other models these mAbs are combined
with myeloablative chemotherapy agents, such as busulfan,
which is an alkylating agent with specific action against
primitive haematopoietic stem cells (HSCs) [12,13], and
immune supressing agents such as sirolimus (rapamycin),
which prevents the action of T and B cells by blocking cytokine
receptors for IL-2 [14]. Combining these mAbs with 20-40mg/kg
busulfan, moderate cell doses (25-40x106) and sirolimus can
generate 60-80% donor chimerism, but only 10-30% with lower
non-myeloablative busulfan doses [15,16]. Costimulation
blockade with anti-CD40L mAb and occasionally CTLA4Ig is
often combined with 3Gy total body irradiation (TBI), generating
5-80% donor chimerism in C57BL/6 recipients with moderate
cell doses (20-40x106) [15,17-20]. Further reduction of TBI in
combination with anti-CD40L reduces chimerism [21], whilst
addition of donor specific transfusion (DST) does not lead to
significant increases [22,23]. Regimens with immune
suppression but no myeloablation all use high cell doses
(50-200x106), and resulting donor chimerism (1-40%) is lower
than regimens involving myeloablation [4,8,9,24]. These
studies show that myeloablation is important in achieving high
donor chimerism, but the relatively high levels of myeloablation
and the permissive conditions used to achieve them make
these regimens an unattractive clinical proposition. In the clinic,
patients often receive a cell dose that is only just sufficient for
repopulation [25], therefore it is unfeasible to overcome graft
rejection using high cell doses.
In summary, few RIC protocols for murine allogeneic HSCT
achieve >80% donor chimerism, and those that do include
moderate myeloablation, multiple immune suppressing agents
and high donor cell doses [15,16,18,26]. In addition, strain
combinations where immune suppression alone can result in
allo-transplant acceptance are used, which is in contrast to the
clinical scenario where both myeloablation and
immunosuppression are required to achieve allo-transplant
engraftment [3]. Lastly, significant long-term donor chimerism
using NMC across an MHC barrier with clinically relevant cell
doses has not been achieved to date, whilst the factors
required to achieve this remain elusive.
In order to improve the stringency of existing allo-transplant
regimens we therefore developed a fully MHC mismatched
mouse model of HSCT using low CBA donor cell doses into
C57BL/6 recipients. This model requires fully myeloablative
busulfan conditioning combined with T cell co-receptor
blockade of signal 1 for long-term graft acceptance. Having
identified that higher syngeneic chimerism in C57BL/6
recipients was associated with an increased ratio of donor to
recipient haematopoietic cells in BM initially after transplant, we
then compared published methods for improving donor to
recipient cell number in the BM niche including ACK2 [27], G-
CSF [28] or high cell dose [7], against further costimulatory
blockade of signal 2 [5], all in combination with RIC and signal
1 blockade in our CBA-C57BL/6 transplant model. Despite
early engraftment with G-CSF or high cell doses, costimulatory
blockade was the only factor that could permit the use of NMC
in combination with signal 1 blockade in this stringent mouse
model of transplantation.
Results
Syngeneic engraftment is influenced by the early ratio
of donor: recipient cells in the BM niche after
transplant
We chose to develop RIC regimens using busulfan, because
it is considered less toxic than irradiation; it is myeloablative but
not immune suppressive and has specific action against
primitive HSCs [12,13]. It is used in many clinical transplant
regimens for genetic diseases [2]. We initially sought to
determine the impact of busulfan conditioning on migration of
donor cells to the BM niche. SDF-1/CXCR4 is the major axis of
donor cell migration to the BM [29]; therefore we determined
the effect of busulfan dose on BM and plasma concentration of
SDF-1α (Figure 1A). Mice receiving 75 and 125mg/kg busulfan
had lower BM SDF-1α than mice receiving 0 or 25mg/kg
(Figure 1B), whilst plasma SDF-1α was not affected (Figure
1C). As a result, the BM: plasma SDF-1α gradient is reduced
with 75 and 125mg/kg busulfan, but is statistically
indistinguishable with 0 and 25mg/kg busulfan (Figure 1D).
To determine the effect of these altered SDF-1α levels on
donor cell migration to the BM, we performed syngeneic HSCT
and determined the number and percentage of donor cells that
homed to BM (Figure 1E). Significantly fewer donor cells
reached the BM in mice receiving 125mg/kg busulfan
compared to either 0 or 25mg/kg, and in mice receiving
75mg/kg busulfan compared to 25mg/kg, with about half as
many donor cells reaching the BM in the higher dose groups
(Figure 1F). However, the number of recipient cells present in
the BM is also significantly reduced in mice receiving busulfan,
particularly at doses of 75 and 125mg/kg (Figure 1G), therefore
the ratio of donor: recipient cells in BM is increased in mice
receiving higher busulfan doses (Figure 1H), due to greater
ablation of recipient cells. Recipients of 0 or 25mg/kg busulfan
have only 2% donor cells in BM, whilst mice receiving 75mg/kg
or 125mg/kg busulfan have significantly greater donor
chimerism of 4-12% and 10-20% respectively (Figure 1H).
We then compared long-term engraftment in mice receiving
either NMC with 25mg/kg busulfan or MAC with 125mg/kg
busulfan [30] (Figure 1I), which we have confirmed is
equivalent in C57BL/6 recipients to 10Gy TBI and generates
full donor chimerism after transplant of 2x106 syngeneic BM
cells [31] (Figures S1A,B). Myeloablative busulfan conditioning
results in 70-80% donor chimerism after 2 weeks, rising to
>90% by 12 weeks post-transplant (Figure 1J). Conditioning
with 25mg/kg busulfan also results in long-term donor
chimerism, although the level of engraftment is reduced.
Recipients of 2x106 cells have average donor chimerism of 4%
after 2 weeks, which increases to 52% by 12 weeks post-
transplant, whilst recipients of 10x106 cells have 12% after 2
weeks, and 76% by 12 weeks post-transplant (Figure 1J). In
mice receiving 25 or 125mg/kg busulfan, the percentage
contribution of different lineages to peripheral blood
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Figure 1.  Syngeneic engraftment is influenced by the early ratio of donor: recipient cells in bone marrow after
transplant.  (A) Mice were conditioned with 0, 25, 75 or 125mg/kg busulfan; the concentration of SDF-1α was measured in (B)
bone marrow and (C) plasma, 24 hours after the last dose of busulfan was administered (n=6 per group). (D) The SDF-1α gradient
between bone marrow and plasma was calculated by dividing the bone marrow SDF-1α concentration by the plasma SDF-1α
concentration. (E) Syngeneic HSCT with 20x106 cells (CD45.2) was performed in recipients (CD45.1) that had received 0, 25, 75 or
125mg/kg busulfan (n=2-6 per group). (F) The number of donor and (G) recipient cells and (H) the percentage of donor cells in the
bone marrow at 18 hours post-transplant were detected using flow cytometry. In B, C, D, F G and H each data point represents one
recipient, horizontal bars are the mean and error bars represent the standard deviation. (I) HSCT recipients (CD45.1) were treated
with 125mg/kg or 25mg/kg busulfan (BU) before receiving 2x106 or 10x106 syngeneic (CD45.2) donor bone marrow cells (n=5 per
group). Donor chimerism in peripheral blood was monitored using flow cytometry at 2, 4, 6, and 12 weeks post-transplant. (J) The
mean percentage donor chimerism over time is shown; error bars represent the standard deviation. (K) The mean percentage
contribution of donor and recipient T cells, monocytes and B cells over time is also shown, as a percentage of the peripheral blood.
doi: 10.1371/journal.pone.0077632.g001
T Cell Blockade in Murine Allogeneic Transplant
PLOS ONE | www.plosone.org 4 October 2013 | Volume 8 | Issue 10 | e77632
demonstrates that at 2 weeks post-transplant the donor
population consists mainly of monocytes, and as the donor
population expands the contribution of T cells and B cells
increases, whilst recipient T cells and B cells are reduced
(Figure 1K).
Therefore reduced SDF-1α associated with high dose
busulfan does reduce homing, but in syngeneic transplant the
amount of recipient cell ablation, and thus the percentage of
donor cells in the BM niche is more important in determining
long-term engraftment levels.
Treatments that increase initial allogeneic chimerism
are not sufficient for long-term engraftment with RIC
To compare RIC regimens in a clinically relevant setting, we
first characterised a mouse model of allo-transplant across a
full MHC barrier using clinically relevant cell doses that require
both myeloablation and immunosuppression to achieve
engraftment. We surmised that transplant from fully MHC
mismatched CBA (H2Dk) or Balb/c (H2Dd) donors to C57BL/6
recipients (H2Db) would be appropriate as C57BL/6 recipients
have increased stem cell numbers [32], and are reportedly
resistant to transplant tolerance induction protocols [5,33].
MAC with 125mg/kg busulfan and transplant with 10x106 cells
from either CBA or Balb/c donors led to rejection in all C57BL/6
recipients, and at 2 weeks post-transplant 70-80% of the
peripheral blood was recipient T cells, demonstrating a large T
cell response to the allogeneic cells (Figures S2A,B). We
therefore included immune suppression, adding non-depleting
anti-CD4 and anti-CD8 mAbs at days 0, 2 and 4 (Figure 2A).
Anti-CD4 and anti-CD8 mAbs are used together because CD4
and CD8 T cells can mediate HSCT rejection independently
[34]. We chose non-depleting mAbs because they allow
generation of T regulatory cells (Tregs) [11,34,35], which are
important in generating transplant tolerance. Combining non-
depleting anti-CD4 and anti-CD8 mAbs with 125mg/kg busulfan
generates full engraftment in C57BL/6 recipients with 10x106
CBA cells, but does not allow significant reduction of the
busulfan dose (Figure 2B). A mixed response is observed with
100mg/kg busulfan, with 3/7 mice developing long-term
engraftment, whilst rejection is observed in all recipients when
busulfan is reduced to 75, 50 or 25mg/kg (Figure 2B).
We therefore chose 75mg/kg busulfan for use in further RIC
regimens as a dose that was just insufficient to attain
engraftment in combination with 1mg anti-CD4 and anti-CD8
antibodies on days 0, 2 and 4 (Figure 2C). Increased or
extended mAb treatments were tested, to ascertain if the
immunosuppressive effect of anti-CD4/8 could be improved.
Treatment with 3mg each mAb on days 0, 2 and 4 did not
improve engraftment or tolerance (Figure 2D). Extension of
treatment to 1mg each mAb on days -1, 0, 2 and 4, or every
day from -1 to 4, improved initial engraftment to 30-80% at 2
weeks post-transplant (Figures 2E,F), but by 12 weeks post-
transplant all mice had no donor chimerism. Improved initial
engraftment did not lead to tolerance once chimerism was lost
(Figures 2E,F).
Given our findings in syngeneic transplant, that donor:
recipient cell ratio in the BM niche plays a key role in attaining
high donor engraftment, we compared regimens designed to
improve donor: recipient cell number. Anti-ckit mAb, ACK2,
was used to disrupt recipient stem cell niche interactions prior
to HSCT, but had no effect on engraftment (Figure 2G). The
use of GSCF to stimulate stem cell proliferation and egress
from the BM niche prior to HSCT improved initial engraftment
in some recipients, but lasting engraftment and tolerance were
not observed (Figure 2H). A high cell dose (100x106 cells),
increasing the potential number of donor cells reaching the
niche, allowed early engraftment in 4/5 recipients, but only 1
retained long-term donor chimerism and gained tolerance to
donor cells (Figure 2I). This suggests that increasing the
proportion of donor: recipient cells in the niche has some
benefit, but is not sufficient to reliably overcome the immune
response in MHC mismatched HSCT.
In all these unsuccessful RIC regimens, any initial donor
chimerism present at 2 weeks post-transplant consisted mostly
of CD11b+ monocytes, whilst the contribution of CD3+ T cells
and CD19+ B cells to the donor population increased gradually
over time only in the single recipient of 100x106 cells that
retained donor chimerism (Figure 2D-I). In all regimens the
percentage of recipient T cells is reduced compared to that
observed in mice that received allotransplant following busulfan
conditioning without mAb treatment (Figure 2D-I, Figure S2B),
though not sufficiently to prevent graft rejection, except in a
single mouse with very high initial donor chimerism (Figure 2I).
Combined signal 1 and 2 T cell blockade is required for
long-term allogeneic BM engraftment with NMC
Following the failure of RIC regimens based on increasing
the ratio of donor: recipient cells in the BM, we attempted to
determine a successful RIC regimen that included additional
immune suppression via costimulatory blockade. In mice that
received 75mg/kg busulfan, anti-CD4/CD8 mAb treatment, plus
1mg of anti-CD40L to block costimulation, transplant with
10x106 CBA cells generated long-term engraftment and
tolerance in 4/5 recipients (Figures S3A,B). We then examined
whether engraftment of 10x106 CBA or Balb/c cells could also
be achieved in C57BL/6 recipients using NMC of 25mg/kg of
busulfan combined with anti-CD4/CD8/CD40L mAb (Figure
3A). We generated long-term donor engraftment and tolerance
to donor splenocytes in recipients of CBA and Balb/c cells,
achieving an average of 65% and 85% donor chimerism
respectively by 20 weeks post-transplant (Figures 3B,C). As
observed in syngeneic transplant, the donor population at 2
weeks post-transplant consists mainly of monocytes, but the
contribution of donor T cells and B cells increases over time
(Figures 3B,C). The recipient T cell population in successful
engraftment does not appear to be significantly smaller than in
the unsuccessful regimens at 2 weeks post-transplant, but
decreases over time as donor chimerism is established
(Figures 3B,C).
To determine whether combination of signal 1 and signal 2 T
cell blockade was necessary for the success of this NMC
regimen, C57BL/6 recipients were treated with 25mg/kg
busulfan and either anti-CD4/CD8 mAb or anti-CD40L mAb
(Figure 3A). A transplant of 10x106 CBA cells was fully rejected
by 2 weeks post-transplant in recipients of either signal 1
(Figure 3D) or signal 2 blockade alone (Figure 3E). The
T Cell Blockade in Murine Allogeneic Transplant
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Figure 2.  Increasing initial allogeneic chimerism is not sufficient for long-term engraftment with reduced intensity
conditioning.  (A) HSCT recipients (C57BL/6) were treated with busulfan conditioning before transplant with 10x106 allogeneic
(CBA) cells, and received 1mg anti-CD4 and anti-CD8 mAb on days 0, 2 and 4 relative to transplant with or without additional
treatments as specified (n=4-6). (B) Donor chimerism at 12 weeks post-transplant was measured using flow cytometry in mice that
had received 25-125mg/kg busulfan plus 1mg anti-CD4 and anti-CD8 mAb on days 0, 2 and 4. (C) Donor chimerism over time is
shown for recipients of 75mg/kg busulfan and 1mg mAb. Tolerance to donor cells at >20 weeks post-transplant, measured using the
in vivo cytotoxicity assay, is presented as ratio of donor: recipient splenocytes remaining in spleen (Sp) and blood (Bl) 20 hours after
injection. Tolerance is indicated by values >0.6. Additional treatments tested in combination with this regimen included (D) an
increased dose of 3mg anti-CD4 and anti-CD8 mAb (n=5), (E) 1mg of each mAb on days -1, 0, 2 and 4 (n=4), (F) 1mg on days -1 to
4 (n=4), (G) 500ug ACK2 treatment on day -7 (n=5), (H) 8ug G-CSF for 4 days before HSCT (n=5), or (I) a cell dose of 100x106 cells
(n=5). Donor chimerism in peripheral blood at 2, 4, 6, 12 and 20 weeks post-transplant, the mean percentage contribution of donor
and recipient T cells, monocytes and B cells in peripheral blood at these time points, and in vivo cytotoxicity assay results from >20
weeks post-transplant are displayed. Where some mice accepted transplant and others rejected, the contribution of different
lineages and the in vivo cytotoxicity results are separated for the mice with and without donor chimerism.
doi: 10.1371/journal.pone.0077632.g002
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percentage of recipient T cells is reduced with either treatment,
compared to that in mice receiving allotransplant following
busulfan conditioning alone, but not sufficiently to allow graft
acceptance (Figures 3D,E). Therefore the combination of these
two treatments is essential for non-myeloablative transplant
success.
To determine whether combined signal 1 and 2 T cell
blockade improved transplant success by having an effect on
the donor: recipient cell ratio in BM, we compared homing in
mice that all received 75mg/kg busulfan with either syngeneic
HSCT (successful engraftment), allogeneic HSCT (rejection),
or allogeneic HSCT with anti-CD4/CD8/CD40L mAb treatment
(successful engraftment) (Figure 4A). The number of donor
cells in BM is significantly reduced after allogeneic HSCT
compared to syngeneic HSCT, but addition of mAb treatment,
which ultimately results in transplant acceptance, does not
increase homing to BM after allo-transplant (Figure 4B). There
is no significant difference in the number of recipient cells in the
Figure 3.  Combined signal 1 and 2 T cell blockade is required for long-term allogeneic engraftment with non-myeloablative
conditioning.  (A) HSCT recipients (C57BL/6) were treated with 25mg/kg busulfan and given allogeneic HSCT with anti-CD4/CD8,
anti-CD40L, or combined mAb treatment. Donor chimerism and the mean percentage contribution of donor and recipient T cells,
monocytes and B cells in peripheral blood at 2-20 weeks post-transplant, and the in vivo cytotoxicity assay results from >20 weeks
post-transplant are displayed. Transplant acceptance was observed in recipients of 10x106 (B) CBA donor cells (n=5), or (C) Balb/c
donor cells (n=6), along with 1mg anti-CD4, anti-CD8 and anti-CD40L mAb on days 0, 2 and 4. Transplant rejection was observed in
recipients of 10x106 CBA donor cells with either (D) 1mg anti-CD4 and anti-CD8 mAb (n=5) or (E) 1mg anti-CD40L (n=6) on days 0,
2 and 4.
doi: 10.1371/journal.pone.0077632.g003
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BM after syngeneic or allogeneic transplant (Figure 4C),
therefore the percentage of donor cells in BM after allo-
transplant with or without mAb treatment is also significantly
reduced compared to syngeneic transplant (Figure 4D). This
confirms that the number of donor cells migrating to BM is less
critical than blocking the immune response in allogeneic
transplant.
Discussion
Many murine RIC HSCT regimens use high cell doses, but in
the clinic patients often receive a dose only just sufficient to
reconstitute the haematopoietic system [25]. Using cell doses
that better reflect the equivalent cell dose a patient may
receive, we found that syngeneic engraftment could be
achieved using a non-myeloablative dose of 25mg/kg busulfan,
increasing over time to up to 80% in recipients of 10x106 cells.
This gradual increase has been observed by others; in
syngeneic HSCT with 20mg/kg busulfan and 20-28x106 cells,
low initial engraftment increased to 70-90% by 12-17 weeks
post-transplant [13,36]. This may be because low dose
busulfan leads to delayed suppression of peripheral blood
counts, reaching a maximum 2-3 weeks after treatment [13,36].
Unlike irradiation, busulfan suppresses HSCs and progenitors
by an apoptosis-independent mechanism, leading to a
decreased frequency of colony forming cells and reduced
colony size from BM taken 7 days after busulfan treatment
[37,38]. This probably means that busulfan treated cells are not
removed immediately but are disadvantaged in comparison to
transplanted cells, allowing gradual engraftment as donor cells
out-compete damaged recipient cells. However, in allogeneic
transplant the immune response against donor cells means
they are unable to out-compete recipient cells without full
myeloablation and immune suppression.
Studies of RIC HSCT have shown that Tregs are important in
generation, but not maintenance, of tolerance [17,39].
Therefore in our allogeneic HSCT model we used non-
depleting T cell blocking mAbs against CD4 and CD8, which
allow generation of Tregs [11,34,35], and are used together
because CD4 and CD8 T cells can independently mediate
HSCT rejection [34]. Non-depleting anti-CD4/CD8 mAbs
overcome allogeneic HSCT rejection in combination with
125mg/kg busulfan, but myeloablation cannot be reduced.
Others have reported that agents inhibiting alloreactive CD4
and CD8 T cell proliferation do not prevent HSCT rejection, and
are not as potent as anti-CD40L costimulation blockade in
allowing HSCT acceptance [26]. Using 200x106 cells,
costimulation blockade generates mixed chimerism [10], but T
cell depleting mAbs against CD4 and CD8 do not [7]. It has
been suggested that costimulation blockade is better than T
cell depletion at overcoming intrathymic alloresistance [7], and
this may extend to non-depleting T cell blockade as we found it
necessary to add anti-CD40L mAb when busulfan dose was
reduced. However anti-CD40L only generates CD4 T cell
tolerance and cannot overcome CD8 T cell mediated graft
rejection [39-41], which is important in human transplant
acceptance. We determined that costimulation blockade alone
was not sufficient for allo-transplant success with NMC, and the
importance of including CD4/CD8 blockade is also
demonstrated by the higher levels of engraftment we achieve
compared to regimens using low dose myeloablation and anti-
CD40L mAb alone, despite their using 2-4 fold higher cell
doses [15,17,18,21]. We have also demonstrated that whilst a
variety of RIC regimens were able to reduce the post-transplant
expansion of recipient T cells, this was not sufficient to prevent
Figure 4.  The success of allogeneic HSCT with combined signal 1 and 2 blockade is not due to increased homing of donor
cells to the bone marrow.  (A) HSCT recipients (C57BL/6) were treated with 75mg/kg busulfan and then received syngeneic
transplant (n=6), allogeneic transplant (n=6), or allogeneic transplant plus 1mg anti-CD4, anti-CD8 and anti-CD40L mAb on the day
of transplant (n=6). (B) The number of donor cells, (C) number of recipient cells, and (D) percentage of donor cells in bone marrow
were determined 36 hours after transplant. Each data point represents one recipient, horizontal bars are the mean and error bars
represent the standard deviation.
doi: 10.1371/journal.pone.0077632.g004
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graft rejection, except in the regimen that combined anti-CD40L
with anti-CD4/CD8 mAbs. This combination of CD4/8 blockade
with costimulation blockade allowed a gradual increase in
donor cells of multiple lineages over time, in a similar way to
that observed in syngeneic transplant.
Myeloablation with irradiation has been reported to increase
SDF-1 production in BM [42]; however in contrast, we observed
a reduction of SDF-1 in BM of recipients treated with increasing
doses of busulfan. Busulfan is delivered over a number of
days, therefore mice receiving higher doses will have
significant cell death and fewer cells remaining in their BM
before transplant. High dose busulfan may induce individual
cells to produce more SDF-1, but reduced cell number means
that overall SDF-1 levels are lower. With high dose busulfan,
the number of syngeneic donor cells that home to BM is also
reduced, correlating with the SDF-1 gradient, and reduced
homing has also been observed in irradiated compared to non-
irradiated mice [43]. However, long-term donor chimerism is
lower after syngeneic HSCT with 25mg/kg compared to
125mg/kg Busulfan, therefore the number of cells homing to
BM is clearly not as important as achieving a high percentage
of donor cells compared to recipient cells. We therefore
attempted to increase the ratio of donor: recipient cells in the
BM of allogeneic HSCT recipients treated with 75mg/kg
busulfan and non-depleting anti-CD4/CD8 mAb. However,
extended mAb treatment, high cell dose, or treatment with G-
CSF did not lead to long-term engraftment, despite increasing
initial engraftment. G-CSF has been used to improve
engraftment via transient mobilisation of stem cells out of the
niche, but in syngeneic rather than allogeneic transplant, using
160cGy irradiation [28]. ACK2 has also been used to deplete
HSCs from the BM niche, allowing 16-90% donor chimerism in
immune deficient recipients [27]. It is likely that these
approaches were unsuccessful in our model as the immune
response could not be overcome by increasing the ratio of
donor: recipient HSCs in the BM niche. This is supported by
our observations that homing is significantly reduced in
allogeneic compared to syngeneic HSCT, but that treatment
with anti-CD4/CD8/CD40L mAb, which allows allo-engraftment,
does not increase homing in allogeneic recipients. Thus
improved homing is not essential, and improving early
engraftment in the BM niche is unlikely to be sufficient for non-
myeloablative HSCT without further immune suppression.
Addition of anti-CD40L costimulatory blockade to anti-
CD4/CD8 mAb treatment allows reduction of busulfan to
25mg/kg. Anti-CD40L mAb is widely used in mouse models of
RIC allogeneic HSCT, but it causes perturbation of blood
coagulation and thromboembolic effects in non-human
primates and humans [44]. However, its inclusion is acceptable
as alternative forms of anti-CD40L mAb lacking the problematic
epitope are as effective [6], whilst anti-CD40 mAbs are also in
development [45]. The combination of anti-CD4, anti-CD8 and
anti-CD40L mAb has also been successful in murine allo-
transplant without myeloablation; however the protocol of
Graca et al only works with certain strain combinations and
was less effective in C57BL/6 syngeneic transplant than in
CBA allogeneic transplant [5]. C57BL/6 mice are reportedly
resistant to CD4/CD8 mAb tolerance induction protocols [33],
possibly because C57BL/6 stem cells are more abundant than
other mouse strains [32], but we overcome this resistance by
adding non-myeloablative busulfan. Anti-CD4/CD8, or anti-
CD40L mAb do not generate allogeneic HSCT acceptance
between strains with major and minor MHC mismatches
without some myeloablation [4], but we agree that in
combination these mAbs work synergistically, as reported by
Graca et al [5]. In their model, low donor chimerism develops in
permissive strains treated with mAb, whilst we achieve higher
donor chimerism in non-permissive strains treated with mAb
and non-myeloablative busulfan.
The RIC regimen developed by Graca et al also includes
pre-treatment of recipients with anti-CD4/CD8 mAb 4 weeks
before transplant, which increases memory and regulatory cells
[5]. Recipients that received no pre-treatment underwent a
protocol that closely resembles our own but generated no
donor chimerism [5]; therefore addition of 25mg/kg busulfan
appears essential. Addition of non-myeloablative busulfan can
greatly reduce the cell dose required for allogeneic
engraftment. With T cell depleting mAbs and sirolimus, addition
of 5-40mg/kg busulfan allowed a 6-fold reduction in the
required cell dose [16], and with costimulation blockade
addition of 20mg/kg busulfan allowed a 100-fold reduction in
cell dose [39]. Our use of 25mg/kg busulfan with signal 1 and 2
T cell blockade allows a clinically relevant cell dose to generate
higher donor chimerism than many other protocols. When the
same antibodies are used with a mAb pre-treatment stage
rather than myeloablation, just 25-40% donor chimerism is
achieved using 2-4 fold higher cell doses [5,6,11]. Compared to
protocols with 3Gy irradiation (which has a similar effect on
white blood cells to 20mg/kg busulfan [39]) and anti-CD40L
mAb we also achieve slightly higher chimerism with fewer cells
[15,17,22,46]. The only protocol that achieves similar levels of
chimerism involves depleting mAbs, 20-40mg/kg busulfan,
sirolimus and 25-40x106 cells [15,16]. However, the use of non-
depleting rather than depleting mAb is preferable for Treg
generation, and there is evidence that sirolimus can boost T
cell responses in some circumstances [47].
In conclusion we have used a stringent mouse model of
allogeneic HSCT that requires full myeloablation and immune
suppression for engraftment, to compare RIC regimens. We
have determined that although in syngeneic transplant
increasing the ratio of donor: recipient cells in the BM niche
positively influences engraftment, improvements in initial
engraftment, either by creating more space in the BM niche, or
by delivering more donor cells, are ineffective in RIC for allo-
transplant. To achieve long-term high donor chimerism in
allogeneic transplant using clinically relevant cell doses and a
non-myeloablative busulfan dose requires immune blockade, of
T cell activation via both signal 1 and 2. Neither signal 1 or 2
blockade alone was sufficient to achieve allotransplant
acceptance thus highlighting the importance of T cell signalling
in the transplant setting. Addition of costimulatory blockade
was critical for reduction of busulfan doses, which is
informative for the clinic, where CTLA4Ig (Abatacept/
Belatacept) is already approved for costimulatory blockade [48]
but is not currently used in HSCT regimens. We would predict
that once T cell responses are effectively blocked during allo-
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transplant, the factors used to achieve improved donor:
recipient numbers in the BM niche could then be used to
achieve maximal donor chimerism.
Materials and Methods
Mice
CBA (H2Dk) and Balb/c (H2Dd) (Harlan, UK), C57BL/6
(CD45.2, H2Db) and B6.SJL-PtprcaPepcb/BoyJ (CD45.1, H2Db)
mice were maintained at the University of Manchester
Biological Services Unit, in a 12/12h light/dark cycle and
constant temperature with access to food and water ad libitum.
All animal procedures were approved by the University of
Manchester Ethical Review Process Committee, and carried
out in accordance with the Animals (Scientific Procedures) Act,
1986 (UK) and Home Office licence PPL40/3117.
Haematopoietic stem cell transplant
Myeloablation.  C57BL/6 recipients (6-12 weeks old)
(n=3-7) received conditioning regimens. MAC used 10Gy TBI
(2 x 5Gy separated by 3-4 hours) on the day of transplant, or
125mg/kg busulfan (Busilvex 6mg/ml, Pierre Fabre), (5 x
25mg/kg/day over 5 days) via intraperitoneal (IP) injection
finishing on day -1 to transplant [49-51]. RIC was achieved by
reducing busulfan to 50, 75 or 100mg/kg (25mg/kg/day). NMC
used one dose of 25mg/kg busulfan. Recipients received
acidified water (pH 2.8) and irradiated food during the period of
immune compromise following conditioning, and dietary
supplementation with mash and jelly to improve post-transplant
weight outcomes.
Immune blockade.  Some groups received non-depleting
mAbs that block CD4 (YTS177), CD8 (YTS105) and CD40L
(MR1), produced from hybridoma cell lines kindly provided by
Prof. H. Waldmann [34,40]. The protocol for mAb production
was modified from Honey et al [40]. Cells were cultured in
CELLine CL 1000 flasks (Integra), in Iscove’s Modified
Dulbecco’s Medium (IMDM) with 5% foetal calf serum (FCS).
Fractionated ammonium sulphate precipitation was used to
purify mAb from the cell culture supernatant. The mAb
solutions were dialysed into phosphate buffered saline (PBS),
concentrated using VivaSpin centrifugal concentration columns
(Sartorius Stedim Biotech), and concentration estimated using
absorbance at 280nm. SDS and native polyacrylamide gel
electrophoresis were used to test for purity and denaturation
respectively.
Standard mAb treatment was 1mg each of anti-CD4 and
anti-CD8 via IP injection on days 0, 2 and 4 relative to
transplant, with additional use as stated. Baytril oral solution,
(0.25mg Enrofloxacin/ml) was given for the duration of mAb
treatment and 1 week afterwards to avoid infections.
Additional factors.  Additional factors were tested in
combination with 25 or 75mg/kg busulfan and anti-CD4/CD8
mAb treatment; 500μg ACK2 (eBioscience) on day -7 via
intravenous (IV) injection [27], 4μg G-CSF (Neupogen, Amgen)
twice daily for 4 days before and once on the day of transplant
via subcutaneous (SC) injection [28], or 1mg anti-CD40L on
days 0, 2 and 4.
Transplant.  Donor BM was isolated as previously described
[52]. Donor cells were delivered via tail vein injection.
Donor chimerism
Haematopoietic chimerism was quantified by measuring the
percentage of donor: recipient cells in peripheral blood (PB),
BM or spleen using flow cytometry (FACS Canto II, FACS
Diva). Donor and recipient cells were distinguished using
antibodies (BD Biosciences) against CD45.1, CD45.2, H2Dk or
H2Db as relevant, and lineage staining against CD19 (B cells),
CD11b (monocytes) and CD3 (T cells) in 5% solutions of
ToPro3 iodide (Invitrogen).
In vivo cytotoxicity assay
The in vivo cytotoxicity assay was modified from Yamazaki et
al [24]. Splenocytes from donor and recipient (1x107) were
stained with 10µM Celltracker Orange CMTMR or 5µM
Celltrace CFSE (Invitrogen), according to the manufacturer’s
instructions, washed, mixed in a 1:1 ratio and delivered via IV
injection to transplant recipients at >20 weeks post-transplant.
After 20 hours, PB and splenocytes were collected and the
donor (CFSE) and recipient (Celltracker Orange) ratio
determined using flow cytometry. Tolerised recipients retain
close to a 1:1 mix of donor and recipient stained splenocytes,
whilst donor rejection is indicated by the reduction or absence
of stained donor splenocytes. Results are presented as
percentage of donor cells/percentage of recipient cells; >0.6
indicates tolerance, <0.6 indicates non-tolerance.
SDF-1α ELISA
PB collected with sodium citrate anti-coagulant was
centrifuged at 1000g to isolate plasma. BM was prepared [52],
then centrifuged at 300g and the supernatant retained for
analysis. SDF-1α levels were tested using the Quantikine
mouse CXCL12/SDF-1α immunoassay (R&D Systems)
following manufacturer’s instructions.
Statistical analysis
Statistical significance was determined using one-way
ANOVA, applying Tukey’s multiple comparisons test and
assuming significance where p<0.05 of a studentised range of
Q.
Supporting Information
Figure S1.  In syngeneic transplant, conditioning with
125mg/kg busulfan or 10Gy irradiation leads to equivalent
long-term chimerism. (A) HSCT recipients (CD45.1) were
conditioned with 125mg/kg busulfan (BU) or 10Gy total body
irradiation (TBI) before receiving 2x106 syngeneic (CD45.2)
donor bone marrow cells (n=5). (B) Mean percentage donor
chimerism in peripheral blood over time is shown; error bars
represent standard deviation.
(TIF)
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Figure S2.  In allogeneic transplant, 125mg/kg busulfan is
insufficient for engraftment. (A) HSCT recipients (C57BL/6)
were treated with 125mg/kg busulfan before allogeneic HSCT
with 10x106 CBA (n=3) or Balb/c (n=6) donor bone marrow
cells. (B) The mean percentage contribution of donor and
recipient T cells, monocytes and B cells to peripheral blood at 2
weeks post-transplant is displayed.
(TIF)
Figure S3.  Combined signal 1 and 2 T cell blockade allows
long-term allogeneic engraftment with reduced intensity
conditioning. (A) HSCT recipients (C57BL/6) were treated
with 75mg/kg busulfan before transplant with 10x106 CBA
donor cells, along with along with 1mg anti-CD4, anti-CD8 and
anti-CD40L mAb on days 0, 2 and 4 (n=5). (B) Donor
chimerism in peripheral blood and the mean percentage
contribution of donor and recipient T cells, monocytes and B
cells to peripheral blood at 2-20 weeks post-transplant, and the
in vivo cytotoxicity assay results from >20 weeks post-
transplant are displayed. The contribution of different lineages
to peripheral blood and the in vivo cytotoxicity results are
separated for the mice with and without donor chimerism.
(TIF)
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